Ria Kakkad (Drug Target Review)2023-02-27T13:39:19
The team used these models to show drug responses and established a CRISPR-screening platform to identify potential therapeutic targets for non-alcoholic fatty liver disease.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-16T07:00:00Z
Author Dr Martin Baraibar
2026-11-13T07:00:00Z
Contributor Dr Panos Roussos, Drug Target Review
2026-09-23T15:00:00
Sponsored by BioIVT
2026-03-25T15:00:00
Sponsored by Yokogawa
2025-05-28T14:00:00
Sponsored by Eurofins DiscoverX
2026-10-01T06:30:00
Sponsored by Promega Corporation
2026-09-03T07:00:00
Contributor Marty Parrish and Steve Hoffmann, Drug Target Review
2026-09-24T06:30:00
Contributor Dr Dan Benjamin, Drug Target Review
Site powered by Webvision Cloud